<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain>The antithrombotic effect of the <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, CRL42796, was examined in canine models of carotid and coronary artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>2 </plain></SENT>
<SENT sid="3" pm="."><plain>In the carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> model, occlusion occurred in <z:hpo ids='HP_0000001'>all</z:hpo> control vessels (time to <z:mp ids='MP_0005048'>thrombosis</z:mp> 47.6+/-8.9 min) </plain></SENT>
<SENT sid="4" pm="."><plain>After treatment with low dose CRL42796 (15 microg kg(-1) loading dose +0.31 microg kg(-1) min(-1) i.v.), two of five vessels occluded </plain></SENT>
<SENT sid="5" pm="."><plain>Time to <z:mp ids='MP_0005048'>thrombosis</z:mp> increased significantly to 155.2+/-23.1 min </plain></SENT>
<SENT sid="6" pm="."><plain>When the drug infusion was increased (0.69 microg kg(-1) min(-1)), each of five vessels remained patent </plain></SENT>
<SENT sid="7" pm="."><plain>3 </plain></SENT>
<SENT sid="8" pm="."><plain>Ex vivo platelet aggregation in response to <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> (AA) and <z:chebi fb="13" ids="16761">ADP</z:chebi> was examined in platelet rich plasma (PRP) prepared from <z:chebi fb="2" ids="50744">citrate</z:chebi> or <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulated blood </plain></SENT>
<SENT sid="9" pm="."><plain>CRL42796 reduced platelet reactivity at low and high doses in PRP from <z:chebi fb="2" ids="50744">citrate</z:chebi> anticoagulated blood </plain></SENT>
<SENT sid="10" pm="."><plain>However, in PRP from <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulated blood, only the higher infusion dose produced a significant reduction in ex vivo platelet responses </plain></SENT>
<SENT sid="11" pm="."><plain>4 </plain></SENT>
<SENT sid="12" pm="."><plain>A combination of oral aspirin (4.6 mg kg(-1) -41, -17 h) and the low infusion dose of CRL42796 did not produce an additional benefit beyond that provided by CRL42796 alone </plain></SENT>
<SENT sid="13" pm="."><plain>5 </plain></SENT>
<SENT sid="14" pm="."><plain>Coronary artery <z:mp ids='MP_0005048'>thrombosis</z:mp> was inhibited in four of five vessels treated with the lower infusion dose of CRL42796 and in five of five vessels treated with the higher infusion </plain></SENT>
<SENT sid="15" pm="."><plain>Time to <z:mp ids='MP_0005048'>thrombosis</z:mp> increased with both doses (Control, 90.8+/-10.4 min; low dose, 165.8+/-14.2 min; high dose, &gt;180.0+/-0 min) </plain></SENT>
<SENT sid="16" pm="."><plain>6 </plain></SENT>
<SENT sid="17" pm="."><plain>The results indicate that CRL42796 is an effective in vivo antithrombotic agent against experimentally-induced carotid and coronary artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>